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Abstract Natural killer (NK) cells contribute to the graft-
versus-leukemia effect after allogeneic stem cell transplanta-
tion. However, the efficacy of NK cell-mediated tumor cell
lysis is limited due to target cell resistance, and target cell-
induced apoptosis (TiA) was proposed to contribute to
differences in susceptibility to NK cells. Here we analyzed
the effects of target cells on the apoptosis of cytokine-
activated NK cells in vitro. We found no association of target
cell susceptibility and TiA of NK cells in an array of human
and murine target-effector cell combinations. Incubation of
NK cells with caspase inhibitors blocked TiA incompletely,
indicating that TiA is partly based on caspase-independent
mechanisms. Modulating NK cell susceptibility against TiA
by caspase inhibition did not influence cytotoxic efficacy.
Furthermore, we found cytotoxic potential of NK cells to be
markedly decreased following first target cell contact.
Exhaustion of NK cell activity by first target cell contact
was, however, not mediated by TiA. In addition, we found no
relevant TiA by lymphoma cell lines against activated murine
NKcells.We concludethatTiArepresentsonlyaminorfactor
of target cell resistance against NK cell-mediated cytolysis.
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Introduction
Natural killer (NK) cells recognize and destroy certain
tumor cells without prior immunization. This phenomenon
has been recognized in numerous in vivo and in vitro
systems in man and mice [1]. The clinical significance of
NK cell-mediated cytotoxicity for tumor eradication has
been demonstrated after haploidentical allogeneic hemato-
poietic stem cell transplantation [2, 3]. However, some
target cells escape the immunosurveillance exerted by NK
cells [2–5].
In principle, three types of target cell resistance may
be distinguished: (1) failure of target cell recognition
(afferent deficit); (2) failure of NK cells to destroy a
recognized target (efferent deficit); and (3) apoptosis of
NK cells induced by target cells (counter attack). The
relevance of deficient target cell recognition and ineffi-
cient target cell lysis has been described and several
mechanisms leading to target cell resistance could be
clarified [6–12]. The counter attack mechanism has been
addressed for the cytolytic efficacy of αβ Tc e l l s ,γδ T
cells, and interleukin (IL)-2 activated NK cells, yet,
yielding contradictory results [13–18].
Initial studies of tumor-induced apoptosis (TiA) in
human IL-2-activated NK cells showed involvement of
FcγRIII (CD16) [19, 20] and CD2 [21]. Those findings
suggested a role of TiA in antibody-dependent cellular
cytotoxicity (ADCC), and that TiA is similar to activation-
induced cell death of T cells. Furthermore, there is evidence
that NK cells secretion of granzyme B is engaged in NK
cells apoptosis upon activation [22]. Furthermore, it was
shown that TiA of activated NK cells occured in the context
of stimulatory natural cytotoxicity receptor (NCR) engage-
ment [23]. Thus, TiA may play a role not only for ADCC
but also for direct cytotoxicity of NK cells against
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DOI 10.1007/s00277-009-0844-1malignant tumor cells. TiA triggered by NCR stimulation
depended on “autocrine” Fas/Fas-ligand signaling and
consecutive caspase-3 involvement. Caspase inhibition in
γδ T cells prevented Fas-induced apoptosis, and in
consequence, γδ T cells maintained cytotoxic efficacy
when repeatedly challenged with lymphoma cells [24].
We, here, addressed the induction of apoptosis in
lymphokine-activated NK cells (LAK) by the different
origin of malignant target cells and assessed cytotoxic
efficacy and TiA of NK cells in parallel. In a second step,
we looked for strategies to shield NK cells against target
cell-induced apoptosis.
Material and methods
Cell culture
Human K562 (derived from CML blast crisis), ML2 (AML
M4 origin) and Jurkat (derived from T-ALL) cell lines and
murine A20 (origin Balb/c mouse with MHC: H-2d), YAC-1
(derived from A/Sn mouse with MHC: H-2a), and WEHI-3
(Balb/c origin) cell lines (DSMZ, Braunschweig, Germany)
were cultured in RPMI-1640 medium with 25 mM HEPES
and GlutaMAX I (Gibco-BRL, Karlsruhe, Germany) contain-
ing 10% heat inactivated fetal calf serum (FCS, Gibco-BRL)
supplemented with penicillin (Sigma, Steinheim, Germany)
and streptomycin (Biochrom, Berlin, Germany; complete
RPMI). The cytotoxic human NK cell line NK-92, a generous
gift from T. Tonn (Institute for Transfusion Medicine and
Immunohematology, Red Cross Blood Donor Service Baden-
Wuerttemberg-Hessen, Frankfurt/Main, Germany), was
cultured in X-vivo medium (BioWhittaker, Apen, Germany)
containing 5% human, CMV negative, AB plasma supple-
mented with 100 U/ml IL-2 (Cell Concepts, Umkirch,
Germany).
NK cell enrichment and immunophenotyping
Human NK cells were obtained by positive enrichment
with immunomagnetic beads against CD56 (Miltenyi,
Bergisch Gladbach, Germany) from mononuclear cells
(MNC) of buffy coat preparations. For immunophenotyp-
ing, the following fluorochrome-conjugated monoclonal
antibodies were used: CD3-FITC (clone SK7), CD4-PE
(clone SK3), CD8-FITC (clone SK1), CD16-FITC (clone
NKP15), and CD56-PE (clone NCAM16.2; all Becton
Dickinson, Heidelberg, Germany). Purity of CD56
positive NK cell preparations was always >90% with
a fraction of CD3 positive cells <5%. To obtain
lymphokine-activated killer cells, the CD56+ NK cells
were exposed to 500 U/ml IL-2 and 100 U/ml IL-12 (cell
concepts) for 18 h. The stimulation conditions were
established previously to obtain maximally activated
effector cells [25].
MicewerepurchasedfromCharlesRiverLaboratories,Inc.
(Wilmington, USA) and maintained at the central animal
facility at specific pathogen-free conditions. All animal
protocols have been approved by the institutional animal
protection committee. Murine NK cells were enriched from
splenic MNC of C57BL/6 mice (MHC: H-2b) by immuno-
magnetic DX5 positive selection (Miltenyi). The purity of
DX5 positive NK cells used for experiments was always
>90%. To obtain maximally activated effector cells, the
stimulation conditions were established in preliminary
experiments (data not shown). Here, freshly isolated NK
cells were activated for 48 h with IL-2 (1,000 U/ml), IL-7
(40 ng/ml), IL-12 (10 ng/ml), and/or IL-18 (100 ng/ml) as
indicated.
Inhibition of apoptosis
For inhibition of apoptosis, Jurkat cells and NK cells were
cultured for 1 hour at 37°C and 5% CO2 as indicated with
or without 50 or 200 µM Z-Val-Ala-DL-Asp(OMe)-
fluoromethylketone (ZVAD, Bachem, Weil, Germany) and
800 µM Ac-Asp-Glu-Val-Asp-aldehyde (DEVD, Bachem).
Washing cells was followed by incubation with 1 µM
daunorubicin (Daunoblastin®, Pfizer, Karlsruhe, Germany)
or coincubation of NK cells with target cells. To measure
apoptosis by annexin V/propidium iodide (PI) staining,
cells were pelleted and resuspended in staining buffer
(10 mM Hepes/NaOH, pH 7.4; 140 mM NaCl; and 5 mM
CaCl2), and PI was conducted at a final concentration of
10 µM, containing 20 µl of annexinV-Fluos (Roche
Diagnostics, Mannheim, Germany) in each milliliter buffer
and subsequently, analyzed on a FACScan.
Cytotoxicity assay
Flow cytometric analysis of NK cell-mediated cytotoxicity
and simultaneous measurement of NK cell necrosis were
performed as previously described [26]. Briefly, target cells
were stained with 0.1 µl/ml of 3 mM 3,3-dioctadecylox
acarbocyanine perchlorate (DiO; Sigma, Munich, Germany)
dissolved in dimethyl sulfoxide (Sigma) for 20 min at 37°C.
Effector cells were incubated with or without caspase
inhibitors as indicated, and thereafter, cells were washed
with complete medium. Appropriate dilutions of effector
cells to obtain indicated effector to target (E:T) ratio were
cocultured with stained target cells for 4 h at 37°C and 5%
CO2. For spontaneous cell death, stained target cells were
cultured in complete RPMI. Samples were implemented as
triplicates. Cells were analyzed on a flow cytometer
(FACScan, Becton Dickinson) identifying DiO stained target
cells, as well as PI positive dead cells by green and red
342 Ann Hematol (2010) 89:341–348fluorescence, respectively. The specific lysis of target cells
and of NK cells was calculated using the following equation:
specific lysis % ðÞ ¼experimental;%   spontaneous % ðÞ =
100   spontaneous% ðÞ   100.
Apoptosis assay
For flow cytometric analysis of NK cell-mediated apoptosis,
target cells of K562, ML2, and Jurkat cell lines were stained
with PKH-26 (Sigma). Effector cells were preincubated with
or without caspase inhibitors as indicated and thereafter,
washed with complete medium. Appropriate cell dilutions to
obtain indicated effector to target (E:T) ratios were cocultured
with stained target cells for 4 h at 37°C and 5% CO2.F o r
spontaneous apoptosis, stained target cells were cultured in
complete RPMI. Apoptosis was measured by annexinV
binding (see above) [27, 28], separating target cells by PKH-
26 specific red fluorescence. The specific apoptosis of
target cells and LAK were calculated using the following
equation: specific apoptosis % ðÞ ¼apoptosis of sample ð
%   spontaneous apoptosis %Þ = 100   spontaneous ð
apoptosis %Þ 100.
Cold target inhibition assay
Consumption of NK cells cytotoxic activity by contact with
target cells was determined in a cold target inhibition assay
as previously described [29]. Briefly, NK-92 effector cells
were incubated with or without target cells at an effector to
target ratio of 1:1 for 4 h at 37°C and 5% of CO2.
Cytotoxicity assays were performed as described above.
Inhibition of K562 lysis by pre/coincubation with target
cells were calculated using the following equation:
inhibition % ðÞ ¼without pre coincubation% with pre  ð
coincubation %Þ = without pre   coincubation %   100.
Statistical analysis
Differences between cohorts of samples with and without
experimental intervention were tested using the Mann–
Whitney U rank sum test applying Statistica software
(StatSoft Inc., Tulsa, USA), and differences with p < 0.05
were considered significant.
Results
Human NK cells
For a detailed dissection of apoptosis versus lytic function
of NK cells, we first established an experimental system to
prevent apoptosis in the effector cells. Caspase inhibitors
such as ZVAD and DEVD prevent apoptosis induction in
other cell systems, and thus, we tested these compounds for
their capacity to prevent apoptosis in Jurkat cells and
activated NK cells. The addition of 50 or 200 µM ZVAD to
Jurkat cells had no influence on proliferation or viability,
and likewise, there were no significant differences in
viability between NK cells with or without caspase
inhibitor treatment (Fig. 1). Following exposure to 1 µM
daunorubicin ZVAD completely prevented daunorubicin-
induced apoptosis in Jurkat cells in a dose-dependent
manner (Figs. 1 and 2). In contrast to Jurkat cells, however,
ZVAD alone had no major influence on chemotherapy-
induced apoptosis in NK cells (Fig. 1) but combination of
200 µM ZVAD plus 800 µM DEVD largely prevented
apoptosis in these cells (Figs. 1 and 2).
Consecutively addressing target cell-induced apoptosis,
we found that K562 and ML2 cells provided pronounced
induction of NK cell apoptosis, whereas, Jurkat cells had
Fig. 1 Caspase inhibitors protect from cytostatic drug induced cell
death. Influence of incubation with indicated doses ZVAD (and
DEVD) on proliferation and viability of T cell line a Jurkat and b
LAK following incubation with or without 1 µM daunorubicin. LAK
were immunomagnetically enriched human NK cells (purity >90%)
after short time incubation with IL-2 and -12. Viable cells are defined
as annexin V and PI negative. Average cell numbers and standard
deviation of viable cells at indicated time points in percent compared
to start of experiment (0 h). Jurkat and LAK cells differ in behavior
over time. So, different appropriate time points were chosen. Data
from four independent experiments are shown
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and 1:10 K562-induced apoptosis in NK cells at propor-
tions of in 14(±6)%, 33(±9)%, and 45(±3)% ML2-induced
NK cell apoptosis, in 9(±3)%, 26(±6)%, and 58(±10)%
Jurkat-induced NK cell apoptosis, and in 9(±1)%, 10(±
5)%, and 24(±5)% of cells, respectively. To shield NK cells
from target cell-induced apoptosis, we preincubated the
cells with optimal concentrations of ZVAD and DEVD.
Addition of ZVAD and DEVD significantly diminished NK
cell apoptosis induced by K562 cells (6 ± 3%, 20 ± 10%,
and 28 ± 8%) and had only minor or no effect on NK cell
apoptosis exerted by ML2 cells (3 ± 3%, 18 ± 3%, and
53 ± 4%) and Jurkat cells (8 ± 5%, 9 ± 5%, and 25 ± 4%),
respectively (Fig. 3).
At effector to target ratios of 10:1, 1:1, and 1:10 NK
cells induced apoptosis to a greater amount in K562 cells
(93 ± 5%, 61 ± 5%, and 11 ± 3%) than in Jurkat cells
(75 ± 10%, 42 ± 13%, and 13 ± 9%). Apoptosis induction
in ML2 was poor (44 ± 4%, 18 ± 4%, and 6 ± 1%).
Importantly, caspase inhibition by ZVAD or DEVD in NK
cells had no significant effect on cytolytic activity (Fig. 4).
Finally, we analyzed the effect of bystander target cells on
the efficacy of NK cell-mediated K562 leukemia cell lysis
in cold target inhibition assays. In such assays, bystander
cells of both the K562 and ML2 cell line were able to
inhibit NK-92-induced lysis of K562 target cells. The
inhibition of K562 cell lysis at an effector to target ratio of
1:1 amounted to 41 ± 13% in case of Jurkat bystander cells,
62 ± 22% in case of K562 bystander cells, and 48 ± 22% in
case of ML2 bystander cells (Fig. 5).
Thus, leukemic target cells efficiently induce NK cell
apoptosis, which can be, in part, overcome by caspase
inhibition in the effector cells.
Murine NK cells
Our findings in the human system raised our interest in a
murine model system. Thus, we performed cytotoxicity
assays of murine NK cells against the lymphoblastic cell
lines A20, YAC-1, and WEHI-3. We found efficient lysis of
YAC-1 cells, as well as less pronounced of A20 cells, and
only poor lysis of WEHI-3 cells. In this setting, NK cell
activation by IL-12 and IL-18 with or without IL-7 resulted
in significantly higher cytotoxic activity than activation by
IL-2 and IL-7 (Fig. 6).
At effector to target ratios of 50:1, 25:1, and 10:1
average lysis of tumor cells in three independent experi-
ments were as follows: A20, 75%, 62%, and 58% (IL-12+
18) and 70%, 56%, and 51% (IL-12+18+7) versus 31%,
15%, and 6% (IL-2+7); YAC-1, 81%, 76%, and 71% (IL-
12+18) and 72%, 76%, and 55% (IL-12+18+7) versus
42%, 31%, and 20% (IL-2+7); and WEHI-3, 26%, 28%,
and 19% (IL-12+18) and 49%, 58%, and 52% (IL-12+18+
7) versus 16%, 13%, and 19% (IL-2+7). Notably, there was
no evidence for relevant tumor cell-induced apoptosis of
cytokine-activated murine NK cells coincubated with A20,
Fig. 2 Caspase inhibitors prevent apoptosis. Influence of incubation
with 1 µM daunorubicin on T cell line a Jurkat and c LAK without
and with prior incubation with b 200 µM ZVAD and d 200 µM ZVAD
plus 800 µM DEVD, respectively. LAK were immunomagnetically
enriched human NK cells (purity >90%) after short time incubation
with IL-2 and -12. Average cell numbers and standard deviation,
annexin V positive (apoptotic) and PI positive (necrotic) cells from
four independent experiments are shown. Because of slower kinetic of
apoptosis, induction in LAK compared to Jurkat, observation periods
are altered according to the different cell types
344 Ann Hematol (2010) 89:341–348YAC-1, or WEHI-3, respectively (Fig. 6). Thus, in the
murine in vitro model, we found no equivalent to target
cell-induced apoptosis as described for activated human NK
cells in vitro.
Discussion
Target cell-induced apoptosis of NK cells and T lympho-
cytes has been proposed as a relevant mechanism of tumor
cells to escape from the attack by immune cells [13–16].
Thus, caspase inhibitor treatment of γδ T cells reduced
activation-induced cell death triggered by Fas/Fas-ligand
and increased antilymphoma efficacy [24]. Here, we
addressed the functional consequences of TiA in NK cells,
and we confirmed that malignant target cells caused
apoptosis in activated human NK cells [14, 16]. However,
we also found that there was no direct association of the
susceptibility of the target cells to NK cell-mediated lysis
and their potential to induce apoptosis in NK cells. K562
and ML2 cells showed the highest potential to induce
apoptosis in NK cells. However, while K562 cells were
highly sensitive to NK cell-mediated killing, the cytolytic
efficacy of NK cells against ML2 was limited. In previous
studies, we had demonstrated that target cell recognition,
and NK cell activation elicited by K562 and ML2 cells
were similar [8]. However, ML2 cells were found resistant
to lysis mainly due to deficient perforin binding [8, 10].
Overall, our results are in line with previous findings that
Fig. 4 Effect of shielding against target cell-induced apoptosis on
cytotoxic activity. Comparison of efficiency in inducing target cell
apoptosis of untreated LAK (full symbols) and shielded LAK (open
symbols) indicates no improvement of cytotoxicity by shielding LAK.
Apoptosis induction by LAK (with or without ZVAD/DEVD
pretreatment) of K562 is high, ML2 poor, and Jurkat intermediate.
LAK were immunomagnetically enriched human NK cells (purity
>90%) after short time incubation with IL-2 and -12
Fig. 3 Impact of caspase inhibitors on target cell-induced apoptosis in
LAK cells. Comparison of target cell-induced apoptosis of untreated
LAK (full symbols) and shielded LAK (open symbols) indicates a
significant decrease in K562 and a less pronounced or no effect in
ML2- and Jurkat-induced apoptosis of shielded LAK. LAK were
immunomagnetically enriched human NK cells (purity >90%) after
short time incubation with IL-2 and -12
Fig. 5 Results from cold target inhibition assays. Inhibition of NK-92-
inducedK562lysisateffectortotargetratioof1:1duetopre/coincubation
with 5×10E4 target cells, as indicated, showed no significant differences
(averages and SD of three independent experiments)
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lular leakage of granzyme B or Fas-triggered apoptosis [22,
23].
To the best of our knowledge, the data of this study
represents the first results on TiA in the murine system. Of
the three target cell lines with different susceptibilities to
LAK cell lysis, neither the highly susceptible cell line
YAC-1, nor the moderately susceptible cell line A20, nor
the resistant cell line WEHI-3 showed significant potential
for inducing apoptotic death in murine LAK cells.
Activating cytokines such as IL-2 and IL-12 have been
demonstrated to induce apoptosis in NK cells and T cells
and to alter the susceptibility to TiA, whereas, IL-7 was
claimed to protect against cytokine-induced apoptosis [30–
32]. In our experiments, IL-12 and IL-18 activated murine
NK cells more efficiently than IL-2. IL-7 further enhanced
NK cells activity against the relatively resistant cell line
WEHI-3. However, none of these cytokines rendered NK
cells susceptible to TiA. Thus, our data do not support the
notion of TiA contributing to target cell resistance in the
murine system.
Caspase-3 mediated signaling has been shown to play a
pivotal role in TiA [23]. In addition, γδ T cells could be
successfully protected against activation-induced apoptosis,
resulting in enhanced cytotoxicity against malignant lym-
phoma cells [24]. Thus, shielding of NK cells against
apoptosis by preincubation with caspase inhibitors might be
envisioned to inhibit TiA and to augment cytolytic activity.
Following this approach, ZVAD, a broad caspase inhibitor
with focus on caspase-1 [33], partially protected NK cells
from daunorubicin-induced apoptosis. However, with addi-
tion of the caspase-3, -1, and -7 inhibitor DEVD [34, 35],
complete protection of NK cells from daunorubicin-induced
apoptosis was achieved. Surprisingly, caspase inhibition did
Fig. 6 Impact of different cytokine combinations on murine NK cell
cytotoxic efficacy and target cell-induced lysis of murine NK cells.
Comparison of NK-induced lysis of A20, YAC-1, and WEHI-3 target
cells. Murine NK cells were obtained as described in “Materials and
methods” section. NK cells were activated by IL-12 and IL-18
; IL-12, IL-18, and IL-7 ; or IL-2 and IL-7 .
Simultaneously, lyses of NK cells were assessed. No significant target
cell-induced lysis of murine NK cells is detected. Average lyses and
SD from three independent experiments at indicated effector to target
ratio (E:T) are shown
346 Ann Hematol (2010) 89:341–348not prevent TiA completely. Intracellular signaling pathways
of apoptosis depend on the trigger mechanism and differ
between cell types. TiA in NK cells seems to be partly
independent of caspase pathways. Complete inhibition of TiA
must probably include blocking of alternative apoptosis
pathways. Others have reported that blocking of tyrosine
kinases with inhibitors, like herbimycin A, may prevent TiA
[16, 20]. However, herbimycin A may influence the
cytotoxic potential of NK cells by inhibiting NK cells
activation.
Preincubation with ZVAD and DEVD did not result to
an improved NK cell-mediated cytolysis of both susceptible
and resistant target cell lines. This finding, together with
our results in the murine system, is a strong argument
against TiA as a major factor of resistance against NK cells.
One reason why shielding of NK cells against TiA may not
be followed by enhanced cytotoxicity could be that any NK
cell, once activated by an appropriate target, is not able to
exert a second cytotoxic hit against a second target.
Alternatively, protection from TiA with caspase inhibitors
could interfere with NK cells cytotoxic efficacy. ZVAD and
DEVD treatments may reduce NK cells cytotoxic reactivity.
If so, protected NK cells could not exert enhanced
cytotoxicity despite prevention of TiA. But, in our cold
target inhibition experiments, preceding incubation with
various target cell lines significantly diminished NK cell
activity even against highly susceptible targets such as
K562 cells. Thus, consumption of NK cells cytotoxic
potential during first target cell contact makes the number
of surviving NK cells, after first contact, an irrelevant
determinant of NK cells cytolytic efficacy. We used NK-92
cells as effector cell population in the cold target inhibition
experiments. NK-92 cells are not regulated by components
of the killer cell immunoglobulin-like receptor (KIR)
system, as they are devoid of KIR expression except
KIR2DL4. Thus, differences in susceptibility to NK-92
cell-mediated lysis depend on activating receptors, e.g.,
NCR and NKG2D (afferent resistance), or on resistance to
the cytolytic mechanisms of NK cells, e.g., perforin,
granzymes, and Fas-ligand (efferent resistance). The cell
lines used in our experiments differed in susceptibility to
NK cell-mediated lysis, but they uniformly exhausted the
cytotoxic potential of the NK cells. This finding suggests a
major role of efferent resistance in our in vitro models
rather than afferent deficits.
In conclusion, we found that target cells susceptibility to
NK cell-mediated cytotoxicity was not associated with TiA
and that TiA was absent in our murine model system.
Furthermore, we found that pharmacological inhibition of
TiA did not improve lytic activity of NK cells and that NK
cells loose cytotoxic capacity during first encounter of
target cells. Taken together, our results raise doubts of a
relevant role of TiA as a mechanism of resistance. Other
mechanisms must contribute to resistance against NK cells
cytotoxicity. Namely, these are afferent and efferent deficit
by either failure of target cell recognition or failure of NK
cells cytotoxic arsenal [6–12]. To overcome target cell
resistance against NK cells, future efforts should focus on
the mechanisms of efferent resistance and on the role of
inhibitory and stimulatory killer cell receptors.
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